Israel-based Protalix BioTherapeutics has signed an agreement with Pfizer to continue managing the development activities of Gaucher disease drug Elelyso.
According to the clinical development agreement, Protalix will continue to manage and fund Elelyso (taliglucerase alfa) ongoing trials while the new studies of the enzyme replacement therapy will be managed by Pfizer.
Israeli company will earn $8.3m clinical development milestone payment from Pfizer.
The USFDA has approved Elelyso in May 2012 while the Israeli Ministry of Health cleared the candidate in September 2012.
Gaucher's disease is a genetic disease caused due to deficiency of the enzyme glucocerebrosidase resulting in the accumulation of the fatty substance in cells and certain organs such as spleen, liver, lungs, bone marrow, and brain.
